Close

Not a member yet? Register now and get started.

lock and key

Sign in to your account.

Account Login

Forgot your password?

Healthcare  // Browsing posts in Healthcare

November 2014 Trends Tracker

Trends Tracker Companies covered: AAPL, AMD, AMZN, ANGI, BABA, BBRY, CBS, CMCSA, CMG, DIS, DISH, DOW, EBAY, EIX, FB, GOOG/GOOGL, HAR, ISRG, KR, KRX:005930, LNKD, MON, MSFT, NFLX, NRG, NVDA, S, SABR, SFM, SIRI, SWY, T, TMUS, TWTR, TWX, TYO:6758, TYO:7974, VZ, WFM, WMT, YELP Click here to download the report (.pdf)   Introduction Welcome to […]

Read more...

Pacira Pharmaceuticals

Pacira Pharmaceuticals

Research Question: Has the FDA warning letter negatively impacted Pacira Pharmaceutical’s Exparel use? Companies Covered: Pacira Pharmaceuticals (PCRX) Report Available: Nov. 26, 2014   Blueshift’s initial research shows the FDA warning letter may be hampering Exparel use while the company awaits FDA approval for a nerve block indication.   Observations PCRX is a specialty pharmaceutical […]

Read more...

Oct 24 2014 Healthcare

U.S. Citizens Unfazed by Ebola, Say Media Coverage Overblown (Poll)

Research Question: Are Americans worried about the Ebola virus in the U.S.? By: Mason Rudy Click here to download the report (.pdf)   Summary of Findings The vast majority of survey respondents are not concerned about Ebola spreading in the United States, and they have not significantly changed their lifestyles in response to the virus entering the country. […]

Read more...

FDA Approval Gives Spectranetics a Window for Moderate Sales Growth

Research Question: Will Spectranetics’ laser atherectomy and PTA become the new standard of treatment for femoropopliteal ISR and be the catalyst for a significant revenue boost? Companies: ABT, BCR, COV, JNJ, SPNC, VOLC By: David Franklin Click here to download the report (.pdf)   Summary of Findings Spectranetics Corp. (SPNC) can expect a moderate sales increase as […]

Read more...

Market Conditions Prime for More Generic-Drug Price Increases

Research Question: Will declining competition and supply shortages in the generic drug segment continue to drive up prices, or will third-party payers, the FDA and Congress intervene? Companies: ABC, ACT, CAH, CVS, IPXL, LCI, MCK, MYL, RAD, TLV:TEVA, TSE:ENL, WAG, WMT By: David Franklin Click here to download the report (.pdf)   Summary of Findings The trend […]

Read more...

Generic Drug Pricing Whisper

Generic Drug Pricing Whisper

Research Question: Will declining competition and shortages in the generic drug segment continue to drive up prices, or will third-party payers, the FDA, and congress intervene? Companies Covered: Endo International plc (ENDP), Lannett Company, Inc. (LCI), Mylan Inc. (MYL), Actavis PLC (ACT) and Teva Pharmaceutical Industries Ltd. (TLV:TEVA/TEVA) Report Available: October 3, 2014   Blueshift’s initial research shows generic […]

Read more...

Aug 11 2014 Biotechnology, Healthcare

Questcor’s Acthar Gel Sales Will Be Challenged by Tightened Guidelines

Research Question: Will Questcor’s growth be derailed by UnitedHealth’s, Cigna’s and Aetna’s limited reimbursement policy for Acthar Gel? Companies: AET, AMGN, CI, GILD, MNK, QCOR, RHHBY, UNH By: David Franklin Click here to download the report (.pdf)   Summary of Findings Questcor Pharmaceuticals Inc.’s (QCOR) Acthar Gel, which represents 95% of the company’s total sales, will face challenges […]

Read more...

Jul 16 2014 Biotechnology, Healthcare

Aegerion’s Juxtapid Likely to See Limited Sales Improvement

Research Question: Is the leveling off of Aegerion’s Juxtapid sales permanent, or will growth return? Companies: AEGR, AMGN, ISIS, PFE, REGN, SNY By: David Franklin Click here to download the report (.pdf)   Summary of Findings Aegerion Pharmaceuticals Inc.’s (AEGR) orphan drug Juxtapid, which treats the extremely rare HoFH lipid disorder, likely will experience only a limited sales […]

Read more...

Although Not to Forecast Level, MDSO’s CTMS Sales Will Grow This Year

Research Question: Can Medidata capitalize on a stronger sales pipeline to reach its projected growth of 20% to 25% despite challenges from innovative competitors? Companies: IBM, MDSO, MRGE, ORCL, QCOM, PRXL By: David Franklin Click here to download the report (.pdf)   Summary of Findings As Blueshift Research found in its Dec. 13, 2013, report, Medidata Solutions Inc. […]

Read more...

Spectranetics Whisper

Spectranetics Whisper

Research Question: Will superior results from the recent EXCITE ISR trial ensure FDA approval and provide a significant revenue boost for Spectranetics? Companies Covered: Spectranetics Corporation (SPNC) Report Available: August 14, 2014   Blueshift’s initial research shows a substantial market for the treatment of Femoropopliteal In-Stent Restenosis with the combination of SPNC’s laser atherectomy and percutaneous transluminal […]

Read more...